6-28275017-A-C
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001023560.4(ZSCAN26):c.539-1178A>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.167 in 152,002 control chromosomes in the GnomAD database, including 2,510 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.17 ( 2510 hom., cov: 32)
Consequence
ZSCAN26
NM_001023560.4 intron
NM_001023560.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.0650
Publications
28 publications found
Genes affected
ZSCAN26 (HGNC:12978): (zinc finger and SCAN domain containing 26) Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Located in cytosol and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.97).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.266 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ZSCAN26 | NM_001023560.4 | c.539-1178A>C | intron_variant | Intron 3 of 3 | ENST00000421553.7 | NP_001018854.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ZSCAN26 | ENST00000421553.7 | c.539-1178A>C | intron_variant | Intron 3 of 3 | 1 | NM_001023560.4 | ENSP00000481707.1 | |||
| ENSG00000276302 | ENST00000621053.1 | c.133+2230A>C | intron_variant | Intron 3 of 3 | 4 | ENSP00000481142.1 |
Frequencies
GnomAD3 genomes AF: 0.167 AC: 25407AN: 151884Hom.: 2505 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
25407
AN:
151884
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.167 AC: 25428AN: 152002Hom.: 2510 Cov.: 32 AF XY: 0.161 AC XY: 11936AN XY: 74348 show subpopulations
GnomAD4 genome
AF:
AC:
25428
AN:
152002
Hom.:
Cov.:
32
AF XY:
AC XY:
11936
AN XY:
74348
show subpopulations
African (AFR)
AF:
AC:
11183
AN:
41398
American (AMR)
AF:
AC:
2186
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
AC:
281
AN:
3472
East Asian (EAS)
AF:
AC:
652
AN:
5170
South Asian (SAS)
AF:
AC:
437
AN:
4826
European-Finnish (FIN)
AF:
AC:
710
AN:
10576
Middle Eastern (MID)
AF:
AC:
14
AN:
290
European-Non Finnish (NFE)
AF:
AC:
9530
AN:
67984
Other (OTH)
AF:
AC:
305
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1048
2096
3144
4192
5240
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
276
552
828
1104
1380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
373
AN:
3476
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.